Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Uriel Bohn
Observed names:
U Bohn,
U. Bohn
Institution:
Hospital Universitario de Gran Canaria Doctor Negrín
Observed institutions:
AstraZeneca (United Kingdom),
Universitat Autònoma de Barcelona,
Pfizer (United States),
Hospital Universitario de Gran Canaria Doctor Negrín,
Vall d'Hebron Hospital Universitari,
International Breast Cancer Study Group,
Vall d'Hebron Institute of Oncology
show all 7
ORCID:
0000-0003-0544-6311
Observed ORCID:
0000-0003-0544-6311
OpenAlex ID:
A5085369227
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
2016
·
Meritxell Bellet
, Kathryn P. Gray
, et al.
·
Journal of Clinical Oncology
·
172
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
2018
·
Isabel Echavarria
, Sara López-Tarruella
, et al.
·
Clinical Cancer Research
·
138
Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
2015
·
Jaime Feliu
, Antonieta Salud
, et al.
·
PLoS ONE
·
45
PDF
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
2017
·
Jaume Capdevila
, José Manuel Trigo
, et al.
·
European Journal of Endocrinology
·
39
PDF
First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
2014
·
J Feliu
, A Salud
, et al.
·
British Journal of Cancer
·
36
PDF
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
·
Clinical Cancer Research
·
23
PDF
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
2019
·
Xabier García-Albéniz
, Vicente Alonso
, et al.
·
The Oncologist
·
18
PDF
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
2017
·
Estela Pineda
, A Salud
, et al.
·
Tumor Biology
·
14
PDF
Abstract P4-14-01: Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis
2019
·
M Bellet
, K Gray
, et al.
·
Cancer Research
·
12
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
2014
·
Jaume Capdevila
, Jose Manuel Trigo Perez
, et al.
·
Journal of Clinical Oncology
·
11
Prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement
2002
·
Uriel Bohn
, José Aguiar
, et al.
·
International Journal of Cancer
·
10
PDF
GEICO1601-ROLANDO: A Multicentric Single Arm Phase II Clinical Trial to Evaluate the Combination of Olaparib and Pegylated Liposomal Doxorubicin for Platinum-Resistant Ovarian Cancer
2019
·
J Alejandro Perez-Fidalgo
, Maria Iglesias
, et al.
·
Future Science OA
·
9
PDF
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer
2004
·
David Aguiar
, Jos� Aguiar
, et al.
·
Cancer Chemotherapy and Pharmacology
·
8
Meningeal and brain metastases in primary malignant pericardial mesothelioma
1994
·
J.L. Gonzalez
, L.M. Martin
, et al.
·
Annals of Oncology
·
8
Phase II Study of Weekly Irinotecan (CPT-11) as Second-Line Treatment of Patients with Advanced Colorectal Cancer
2003
·
J. Cassinello
, P. López-Alvarez
, et al.
·
Medical Oncology
·
7
Data from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
·
1
Abstract PS16-07: Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
·
Cancer Research
·
1
The androgen receptor gene polymorphisms in human breast cancer: short CAG repeats are associated with lymph node involvement
2005
·
E Betancor
, F. Diaz Rodriguez
, et al.
·
Acceda (Universidad de Las Palmas de Gran Canaria)
·
1
Adverse anaphilactoid reaction of oxaloplatin
2002
·
Uriel Bohn
, José Aguiar
, et al.
·
Revista de Oncología
·
1
Data from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
PDF
Supplementary Methods S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
Supplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
Supplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024
·
Miguel Martín
, Rachel Yoder
, et al.
Show more works
View as search
Works count:
54
Citation count:
554
H-index:
10
I10-index:
11
Year
Topic
Type